# MaxCyte Agrees to Acquire Akron Bio in $151.8 Million Deal By John Kim Canonical URL: https://www.tokenpost.com/news/business/54293 Published: 2026-11-11T18:00:29.000Z Updated: 2026-11-11T18:00:29.000Z Section: Business > The proposed transaction includes $105 million in cash, shares valued at about $26.8 million and $20 million in guaranteed deferred payments. MaxCyte, Inc. agreed to acquire Akron BioProducts LLC, also known as Akron Bio, for $151.8 million in a proposed transaction that remains subject to closing conditions. MaxCyte entered the agreement Nov. 9 and announced it Nov. 10. The proposed consideration includes $105 million in cash, 20,639,733 MaxCyte shares valued at about $26.8 million and $20 million in guaranteed deferred payments. MaxCyte's third-quarter 2026 revenue was $10.2 million, up 49% from a year earlier. Core revenue was $8.2 million. An [earlier preliminary estimate of third-quarter core revenue]() put the figure at about $8.1 million. The acquisition must satisfy closing conditions before it can be completed. ## Links in this article - [earlier preliminary estimate of third-quarter core revenue](https://www.tokenpost.com/news/business/31865)